Combining targeted therapy with immunotherapy (interferon-α) rational, efficacy in gastrointestinal stromal tumor model and implications in other malignancies

Lei L. Chen; Launce Gouw; Mahyar Sabripour; Wen Jen Hwu; Robert S. Benjamin

doi:10.4161/onci.19729

Combining targeted therapy with immunotherapy (interferon-α) rational, efficacy in gastrointestinal stromal tumor model and implications in other malignancies

Lei L. Chen, Launce Gouw, Mahyar Sabripour, Wen Jen Hwu, Robert S. Benjamin

Research output: Contribution to journal › Article › peer-review

11 Scopus citations

Abstract

Imatinib revolutionized gastrointestinal stromal tumor (GIST) treatment but median-progression-free-survival of unresectable/metastatic disease is < 2 y. B-RAFV600-mutated-melanoma responds to vemurafenib dramatically but median-progression-free-survival is < 9 mo. Combining imatinib with immunotherapy (peginterferon α-2b) in GIST showed significant induction of antitumor immunity and highly promising clinical outcomes. This strategy warrants further testing in other malignancies.

Original language	English (US)
Pages (from-to)	773-776
Number of pages	4
Journal	OncoImmunology
Volume	1
Issue number	5
DOIs	https://doi.org/10.4161/onci.19729
State	Published - 2012

Keywords

Drug-resistance
Gastrointestinal stromal tumor
Imatinib
Immunotherapy
Interferon-a
Peginterferon a-2b
Targeted therapy

ASJC Scopus subject areas

Immunology and Allergy
Immunology
Oncology

Access to Document

10.4161/onci.19729

Cite this

@article{842bfbbde7fb4416a9a0ec9771814854,

title = "Combining targeted therapy with immunotherapy (interferon-α) rational, efficacy in gastrointestinal stromal tumor model and implications in other malignancies",

abstract = "Imatinib revolutionized gastrointestinal stromal tumor (GIST) treatment but median-progression-free-survival of unresectable/metastatic disease is < 2 y. B-RAFV600-mutated-melanoma responds to vemurafenib dramatically but median-progression-free-survival is < 9 mo. Combining imatinib with immunotherapy (peginterferon α-2b) in GIST showed significant induction of antitumor immunity and highly promising clinical outcomes. This strategy warrants further testing in other malignancies.",

keywords = "Drug-resistance, Gastrointestinal stromal tumor, Imatinib, Immunotherapy, Interferon-a, Peginterferon a-2b, Targeted therapy",

author = "Chen, {Lei L.} and Launce Gouw and Mahyar Sabripour and Hwu, {Wen Jen} and Benjamin, {Robert S.}",

year = "2012",

doi = "10.4161/onci.19729",

language = "English (US)",

volume = "1",

pages = "773--776",

journal = "OncoImmunology",

issn = "2162-4011",

publisher = "Landes Bioscience",

number = "5",

}

TY - JOUR

T1 - Combining targeted therapy with immunotherapy (interferon-α) rational, efficacy in gastrointestinal stromal tumor model and implications in other malignancies

AU - Chen, Lei L.

AU - Gouw, Launce

AU - Sabripour, Mahyar

AU - Hwu, Wen Jen

AU - Benjamin, Robert S.

PY - 2012

Y1 - 2012

N2 - Imatinib revolutionized gastrointestinal stromal tumor (GIST) treatment but median-progression-free-survival of unresectable/metastatic disease is < 2 y. B-RAFV600-mutated-melanoma responds to vemurafenib dramatically but median-progression-free-survival is < 9 mo. Combining imatinib with immunotherapy (peginterferon α-2b) in GIST showed significant induction of antitumor immunity and highly promising clinical outcomes. This strategy warrants further testing in other malignancies.

AB - Imatinib revolutionized gastrointestinal stromal tumor (GIST) treatment but median-progression-free-survival of unresectable/metastatic disease is < 2 y. B-RAFV600-mutated-melanoma responds to vemurafenib dramatically but median-progression-free-survival is < 9 mo. Combining imatinib with immunotherapy (peginterferon α-2b) in GIST showed significant induction of antitumor immunity and highly promising clinical outcomes. This strategy warrants further testing in other malignancies.

KW - Drug-resistance

KW - Gastrointestinal stromal tumor

KW - Imatinib

KW - Immunotherapy

KW - Interferon-a

KW - Peginterferon a-2b

KW - Targeted therapy

UR - http://www.scopus.com/inward/record.url?scp=84886944075&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84886944075&partnerID=8YFLogxK

U2 - 10.4161/onci.19729

DO - 10.4161/onci.19729

M3 - Article

C2 - 22934279

AN - SCOPUS:84886944075

SN - 2162-4011

VL - 1

SP - 773

EP - 776

JO - OncoImmunology

JF - OncoImmunology

IS - 5

ER -

Combining targeted therapy with immunotherapy (interferon-α) rational, efficacy in gastrointestinal stromal tumor model and implications in other malignancies

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this